4//SEC Filing
WG Biotech ApS 4
Accession 0001753193-25-000004
CIK 0001722964other
Filed
Sep 17, 8:00 PM ET
Accepted
Sep 18, 9:39 PM ET
Size
7.4 KB
Accession
0001753193-25-000004
Insider Transaction Report
Form 4
WG Biotech ApS
Director10% Owner
Transactions
- Disposition from Tender
Common Stock
2025-09-16$8.60/sh−4,559,233$39,209,404→ 0 total
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").
- [F2]Pursuant to the terms of the Merger Agreement, the Shares were tendered at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive $8.60 per Share, in cash, without interest, subject to any applicable withholding of taxes (the "Merger Consideration"). At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the "Effective Time"), each issued and outstanding Share was cancelled in exchange for the Merger Consideration.
Documents
Issuer
Y-mAbs Therapeutics, Inc.
CIK 0001722964
Entity typeother
IncorporatedDenmark
Related Parties
1- filerCIK 0001753193
Filing Metadata
- Form type
- 4
- Filed
- Sep 17, 8:00 PM ET
- Accepted
- Sep 18, 9:39 PM ET
- Size
- 7.4 KB